This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary TNFα Therapeutic Antibody Development
BioVenic provides veterinary TNFα therapeutic antibody development services covering the full antibody development workflow, aiming to deliver more effective therapeutic options for companion animals including canines and felines. TNFα plays a vital role in the onset and progression of chronic inflammation, autoimmune disorders, and multiple cancers in companion animals. Therapeutic antibodies targeting TNFα can alleviate inflammatory responses and thereby open new opportunities for disease treatment.
Background of TNFα
| Full Name | Tumor necrosis factor-alpha |
|---|---|
| Aliases | DIF, TNF, TNF-alpha, TNFA, TNLG1F, TNFSF2. |
| Target Profile | As a pro-inflammatory cytokine belonging to the tumor necrosis factor superfamily, TNFα is primarily produced by activated macrophages. It plays a pivotal role in regulating immune responses, inflammation, cell proliferation, apoptosis, and lipid metabolism by binding to its specific receptors, TNFR1 and TNFR2. |
MoA of TNFα
Upon binding with its receptors TNFR1 and TNFR2, TNF-α activates several signaling pathways that regulate cell survival and death. Activation of TRADD upon TNF-α binding to TNFR1 initiates a cascade of interactions, leading to caspase 3 activation and cell apoptosis. Another pathway through TNFR1 involves TRAF2 recruitment, phosphorylating NF-κB, and mediating the transcription of proteins involved in inflammation and cellular survival. The binding of TNF-α and TNFR1 also activates the MAPK pathway through TRAF2, leading to the activation of c-JNK and the translocation of transcription factors such as AP-1 to the nucleus, triggering cellular responses of apoptosis and survival.
Fig.1 Schematic diagram of TNF-α signaling pathways.1,2
Application in Veterinary Therapeutics
TNFα is a key mediator in various chronic inflammatory and autoimmune diseases in companion animals, targeted by therapeutic antibodies that specifically bind to TNFα, inhibiting its interaction with receptors TNFR1 and TNFR2. This blockade suppresses the inflammatory and apoptotic signaling pathways triggered by TNFα, effectively controlling the progression of these diseases. Additionally, TNFα contributes to tumor growth and spread in certain cancer types by fostering an inflammatory and immunosuppressive environment. Thus, TNFα antibodies can also serve as an adjunct therapy to inhibit tumor growth and dissemination.
Veterinary TNFα Therapeutic Antibody Development Services
BioVenic offers comprehensive veterinary TNFα therapeutic antibody development services, assisting in providing innovative treatment options for companion animals, particularly when traditional therapies are ineffective or cause side effects. Our services extend from gene synthesis to the final production of antibodies, encompassing design, preparation, purification, and detailed verification of biological activity. We employ advanced technologies such as hybridoma, single B cell, and phage display techniques, ensuring strict quality control throughout the development process. We also offer species-specific antibody development services, catering effectively to the needs of specific companion animal species.
Please click the link below for more information about our veterinary TNFα therapeutic antibody development services.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
Our team is experienced in various aspects of veterinary therapeutic antibody development, including antigen preparation, gene synthesis, animal immunization, antibody preparation, antibody engineering, and so on.
We provide heterologous antibody caninization/felinization, as well as affinity maturation services, maintaining high affinity while ensuring low immunogenicity to facilitate pharmacological research.
Our team implements stringent quality controls throughout the veterinary therapeutic antibody development process, including analysis and testing of antibody purity and stability, to maintain high quality and batch consistency.
Frequently Asked Questions
What dual downstream signaling branches are triggered after TNFα binds TNFR1 receptors in companion animal cells?
After TNFα combines with TNFR1, two opposite functional cascades are activated: The TRADD-FADD-caspase axis induces cell apoptosis. Meanwhile TRAF2 mediates NF-κB and MAPK/AP-1 pathways to drive massive pro-inflammatory gene transcription and sustain cell survival. TNFR2 further amplifies inflammatory signals via the TRAF-NIK-IKK module.
What two major categories of companion animal disorders can anti-TNFα neutralizing antibodies be applied to research?
First, chronic inflammatory and autoimmune diseases triggered by excessive TNFα secretion. Second, malignant tumors, where sustained TNFα builds an inflammatory, immunosuppressive tumor microenvironment to facilitate tumor proliferation and metastasis.
What core therapeutic mechanism do veterinary anti-TNFα antibodies adopt to relieve inflammatory lesions?
Therapeutic antibodies specifically bind soluble and cell-membrane TNFα molecules, completely blocking TNFα from docking to TNFR1/TNFR2 receptors. This cuts off all downstream inflammatory and apoptotic signaling cascades, reducing immune cell infiltration and alleviating tissue inflammatory damage in dogs and cats.
What multi-antibody discovery pipelines are available for developing species-specific TNFα antibodies for pets?
We offer four independent screening platforms: mouse hybridoma technology, primary B cell sorting directly isolated from canine/feline blood, multi-round phage display biopanning, and transgenic mouse hybridoma systems for high-specificity anti-TNFα antibody acquisition.
What complete post-screening engineering and validation packages do we provide for TNFα antibodies?
We support CDR grafting, caninization/felinization and affinity maturation to lower in vivo immunogenicity, plus full functional verification assays to confirm the antibody's capacity to block TNFα-mediated NF-κB activation and inflammatory cytokine secretion at the cellular level.
Partner with BioVenic
Overexpression or dysregulation of TNFα can lead to overactivation of the immune system in companion animals, exacerbating inflammation and autoimmune diseases. Using TNFα therapeutic antibodies to modulate or inhibit its action may effectively control the pathological processes of these diseases. BioVenic offers veterinary TNFα therapeutic antibody development services, helping you explore the potential to control inflammation progression. If you are interested in our services, please do not hesitate to contact us now!
References
- Ciebiera, Michał, et al. "The role of tumor necrosis factor α in the biology of uterine fibroids and the related symptoms." International journal of molecular sciences 19.12 (2018): 3869.
- Image retrieved from Figure 2 "TNF-α receptors, pathways and different types of signals—schematic diagram." Ciebiera, Michał, et al., 2018, used under [CC BY 4.0], the image title was changed to "Schematic diagram of TNF-α signaling pathways."